Results 41 to 50 of about 13,248 (184)

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections

Antibiotics
Nosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge. Here, we review pharmacokinetic and pharmacodynamic data and
Roland Nau, Jana Seele, Helmut Eiffert
doaj   +1 more source

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Interpretation of Key Updates in the 36th Edition of Clinical and Laboratory Standards Institute M100 Standard

iLABMED, EarlyView.
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley   +1 more source

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

mBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai, William C. Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Micah M. Bhatti, Ryan K. Shields, Samuel A. Shelburne, Yohei Doi   +10 more
doaj   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study

, 2023
Haiyang Meng,1,2 Yongmei Zhao,1,2 Qi An,1,2 Baoling Zhu,3 Zhe Cao,4 Jingli Lu1,2 1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Henan Key Laboratory of Precision Clinical Pharmacy ...
An Q, Cao Z, Lu J, Zhu B, Meng H, Zhao Y
core  

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics, 2023
Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard, Elizabeth D. Hermsen, Michal Kantecki, Francis F. Arhin   +3 more
doaj   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China

Frontiers in Cellular and Infection Microbiology, 2021
ObjectivesThe aim of this work was to investigate the activity of ceftazidime–avibactam (CZA) and aztreonam–avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs).MethodsNon-duplicate CROs, including 56 carbapenem ...
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao   +7 more
doaj   +1 more source